By Mill Chart
Last update: Jan 4, 2024
Our stock screener has singled out BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as a promising choice for dividend investors. NYSE:BMY not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.
ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NYSE:BMY was assigned a score of 7 for dividend:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NYSE:BMY, the assigned 5 reflects its health status:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:BMY has achieved a 8:
More Best Dividend stocks can be found in our Best Dividend screener.
For an up to date full fundamental analysis you can check the fundamental report of BMY
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
BRISTOL-MYERS SQUIBB CO
NYSE:BMY (4/19/2024, 11:40:07 AM)
48.575
+0.28 (+0.57%)
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
If you want to outperform the S&P 500, consider these undervalued dividend stocks for juicy yields and high total return potential.
These income stocks look like good options at current levels.
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The future of the U.S. economy appears promising, with robust growth and strong...
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bristol Myers" or the "Company") (NYSE: BMY)....